Switching off resistance: Lixa’s bold AMR bet

Feb. 3, 2026

Lixa Pty Ltd. has formed a partnership with the Global Antibiotic Research & Development Partnership and announced a AU$28 million (US$20 million) series B round to take Neox-121 to the clinic to fight antimicrobial resistance.

Today's news in brief

BioWorld

BioWorld briefs for May 11, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Hantavirus is ‘sentinel’ more than acute pandemic threat

BioWorld

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...

Infensa Bioscience identifies new ASIC blockers

BioWorld Science

Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.

Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst

BioWorld

Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...